Nachrichten

LABATEC PHARMA ANNOUNCES AN EXCLUSIVE LICENSING AGREEMENT SIGNED WITH AFT PHARMACEUTICALS, TO COMMERCIALISE MAXIGESIC IV®, IN SWITZERLAND   Geneva, March 27, 2023 – Labatec Pharma SA (Labatec) signed a new licensing agreement with AFT Pharmaceuticals (NZX.AFT, ASX.AFP), for the exclusive rights to commercialise Maxigesic IV® in Switzerland, a treatment for mild to moderate pain for use […]

Wir wissen, dass es verschiedene Werkzeuge gibt, um das Virus zu eliminieren, und um die Krebserkrankungen zu verhindern, die das Papillomavirus verursachen kann. Papilocare® ist die erste Therapie zur Vorbeugung und Behandlung von zervikalen niedriggradigen Läsionen, die durch das Papillomavirus verursacht werden: weitere Informationen finden Sie unter www.papilocare.ch oder schreiben Sie uns an papilocare@labatec.com. Sagen […]

LABATEC PHARMA ANNOUNCES EXCLUSIVE LICENSING AGREEMENT SIGNED WITH RADIUS HEALTH INC, TO COMMERCIALISE TYMLOS IN SWITZERLAND AND THE MIDDLE EAST NORTH AFRICA REGION   Geneva, June 9, 2022 – Labatec Pharma SA (Labatec) signed a new licensing agreement with Radius Health, Inc. (Radius) (NASDAQ: RDUS), for the rights to commercialise TYMLOS® (abaloparatide), a subcutaneous injection […]